Holen Sie sich die Stockscreener-App
1.17
14.60%
-0.20
Handel nachbörslich:
1.17
Immunic Inc Aktie (IMUX) Neueste Nachrichten
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Nigeria
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Immunic, Inc. Announces Participation in Investor Conferences Scheduled for March 2026 - geneonline.com
Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions - Dentons
IMUX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunic to Participate in Investor Conferences in March - The Malaysian Reserve
Immunic to present at healthcare investor conferences in March - Yahoo Finance
Immunic execs line up March investor Q&As and webcasts - Stock Titan
Head to Head Review: Neuphoria Therapeutics and Immunic - National Today
Reverse stock split vote at Immunic (NASDAQ: IMUX) tied to Nasdaq listing - Stock Titan
Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight - Barchart.com
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
H.C. Wainwright cuts Immunic stock price target on share count changes - Investing.com Australia
HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price - MarketBeat
Aug Opening: Can Immunic Inc sustain earnings growthMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Immunic secures $400M to support late-stage MS trialsICYMI - Yahoo Finance
Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
COMMODORE CAPITAL LP Acquires Significant Stake in Immunic Inc - GuruFocus
BVF group details large Immunic (IMUX) pre-funded and common warrants - Stock Titan
IMMUNIC (IMUX) director Robert Nagel files initial insider Form 3 - Stock Titan
Immunic CEO on $400m financing, phase 3 MS plans - Proactive financial news
Immunic sets stage for phase 3 MS data readout after $400M financing - Proactive financial news
Immunic: Fourth Quarter Financial Overview - Bitget
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic: Q4 Earnings Snapshot - Barchart.com
Immunic (NASDAQ: IMUX) details 2025 loss and $200M private placement - Stock Titan
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Commodore holds 13.35M IMUX shares, mostly warrant-based (IMUX) - Stock Titan
Trails Edge reports 11.45M-share position in Immunic (IMUX) via warrants - Stock Titan
Why did IMUX stock surge 33% pre-market today? - MSN
IMUX Stock Price, Forecast & Analysis | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
What’s the beta of Immunic Inc. stock2025 Earnings Impact & Long-Term Investment Growth Plans - mfd.ru
Why Immunic Inc. stock is seen as undervaluedJuly 2025 Macro Moves & Safe Entry Trade Reports - mfd.ru
Vivo Opportunity files for Immunic (IMUX): 9.99% stakes via exercisable warrants - Stock Titan
What Does the Market Think About Immunic Inc? - Benzinga
Immunic Therapeutics - The Pharma Letter
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Immunic rises after $400M private placement, leadership transition - MSN
Immunic closes $200 million financing, may receive additional $200m By Investing.com - Investing.com Australia
Funding to support Immunic Phase 3 MS trials, commercialization - Multiple Sclerosis News Today
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):